Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yehuda Handelsman

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 26, 2014
American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive actionW Timothy Garvey, Alan J Garber, Jeffrey I Mechanick, et al.
Hepatology Communications|May 7, 2025
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United StatesJeffrey V Lazarus, Trenton M White, Alina M Allen, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 25, 2017
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASEPaul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, et al.
BMJ Open|July 16, 2024
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristoneRalph A DeFronzo, Richard J Auchus, Irina Bancos, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 14, 2024
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks TreatmentElena A Christofides, Andrzej Stankiewicz, Douglas Denham, et al.
Annals of Hepatology|March 13, 2026
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. citiesJeffrey V Lazarus, Trenton M White, Melina Manolas, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 20, 2003
American College of Endocrinology position statement on the insulin resistance syndromeDaniel Einhorn, Gerald M Reaven, Rhoda H Cobin, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 11, 2008
Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical EndocrinologistsAlan J Garber, Yehuda Handelsman, Daniel Einhorn, et al.
Journal of Diabetes and Its Complications|January 20, 2023
Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseasesYehuda Handelsman, Javed Butler, George L Bakris, et al.
The Lancet. Diabetes & Endocrinology|September 21, 2017
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 26, 2014
American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive actionW Timothy Garvey, Alan J Garber, Jeffrey I Mechanick, et al.
Hepatology Communications|May 7, 2025
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United StatesJeffrey V Lazarus, Trenton M White, Alina M Allen, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|April 25, 2017
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASEPaul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, et al.
BMJ Open|July 16, 2024
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristoneRalph A DeFronzo, Richard J Auchus, Irina Bancos, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 14, 2024
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks TreatmentElena A Christofides, Andrzej Stankiewicz, Douglas Denham, et al.
Annals of Hepatology|March 13, 2026
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) among primary care providers in the four most populous U.S. citiesJeffrey V Lazarus, Trenton M White, Melina Manolas, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|August 20, 2003
American College of Endocrinology position statement on the insulin resistance syndromeDaniel Einhorn, Gerald M Reaven, Rhoda H Cobin, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|November 11, 2008
Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical EndocrinologistsAlan J Garber, Yehuda Handelsman, Daniel Einhorn, et al.
Journal of Diabetes and Its Complications|January 20, 2023
Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseasesYehuda Handelsman, Javed Butler, George L Bakris, et al.
The Lancet. Diabetes & Endocrinology|September 21, 2017
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trialMarc S Sabatine, Lawrence A Leiter, Stephen D Wiviott, et al.
Pageof 16